162 related articles for article (PubMed ID: 7851482)
1. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
[TBL] [Abstract][Full Text] [Related]
2. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
Takiguchi Y; Asai F; Wada K; Nakashima M
Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
[TBL] [Abstract][Full Text] [Related]
4. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
[TBL] [Abstract][Full Text] [Related]
5. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
Yamada K; Tsuji H; Kimura S; Kato H; Yano S; Ukimura N; Yamada Y; Nakagawa K; Nakagawa M
Thromb Res; 2003 Jan; 109(1):55-64. PubMed ID: 12679132
[TBL] [Abstract][Full Text] [Related]
6. A chemiluminescent detection of superoxide radical produced by adherent leucocytes to the subendothelium following thrombolysis: studies with a photochemically induced thrombosis model in the guinea pig femoral artery.
Wada K; Umemura K; Nishiyama H; Saniabadi AR; Takiguchi Y; Nakano M; Nakashima M
Atherosclerosis; 1996 May; 122(2):217-24. PubMed ID: 8769684
[TBL] [Abstract][Full Text] [Related]
7. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
Fitzgerald DJ; Fitzgerald GA
Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7585-9. PubMed ID: 2508092
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
Umemura K; Kawai H; Ishihara H; Nakashima M
Jpn J Pharmacol; 1995 Mar; 67(3):253-8. PubMed ID: 7630043
[TBL] [Abstract][Full Text] [Related]
9. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
Mellott MJ; Connolly TM; York SJ; Bush LR
Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
[TBL] [Abstract][Full Text] [Related]
10. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
Umemura K; Nishiyama H; Kikuchi S; Kondo K; Nakashima M
Thromb Haemost; 1996 Nov; 76(5):799-806. PubMed ID: 8950793
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T; Gold HK; Yaoita H; Leinbach RC; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
J Am Coll Cardiol; 1990 Sep; 16(3):714-22. PubMed ID: 2117620
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
Umemura K; Wada K; Uematsu T; Nakashima M
Stroke; 1993 Jul; 24(7):1077-81; discussion 1081-2. PubMed ID: 8322383
[TBL] [Abstract][Full Text] [Related]
14. Arterial thrombosis model with photochemical reaction in guinea-pig and its property.
Takiguchi Y; Hirata Y; Wada K; Nakashima M
Thromb Res; 1992 Aug; 67(4):435-45. PubMed ID: 1412222
[TBL] [Abstract][Full Text] [Related]
15. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig.
Hirata Y; Takiguchi Y; Wada K; Matsuno H; Umemura K; Uematsu T; Nakashima M
Eur J Pharmacol; 1993 Feb; 231(3):421-5. PubMed ID: 8449234
[TBL] [Abstract][Full Text] [Related]
16. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M
Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999
[TBL] [Abstract][Full Text] [Related]
17. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
[TBL] [Abstract][Full Text] [Related]
18. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
19. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
20. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
